Antithrombotic and Thrombolytic Agents
Keywords:
-Abstract
-
Downloads
References
Hirsh J. Heparin. N Engi J Med 1991;324:1565-74.
Hirsh J, Raschke RA, Warkentin TE, et al. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258-75.
Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Huemost 1992:67.639-43.
Weitz JI, Hudoba M, Mussel D, et al. Clot-bound thrombin is protected from inhibition by heparin-anti-thrombin but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation 1980,61.808-14.
EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/Ila receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, Ohman EM, Leimbergerger JD, Mark DB, Califf RM for the TAMI Study Group. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1995;76:1007-13.
Granger CB, Hirsh J, Calif RM, Col J, White HD, Betriu Am Woodliet LH, Lee KI, Bovill EG, Simes J, Topol EJ for the GUSTO-I investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the
GUSTO-I trial. Circulation 1996;93:870-8.
Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1993;327:141-5.
Flather M, Weitz J, Campeau J, Schuld R, Johnston M, Johnston M, Pogue J, Jessel A, Theroux P, Yusuf S for the OASIS Pilot Study Investigators. Evidence for rebound activation of the coagulation system after cessation of intravenous anticoagulant therapy for acute
myocardial ischemia [Abstract]. Circulation 1995;92:1-485.
Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-8.
Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
Warkentin TE, Levine MN, Hirsh J, et at. Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primanly at home with unfractionated heparin administered in the hospital for proximal deepvein thrombosis. N Engl J Med 1996;334:677-81.
Koopman MMW, Prandoni P, Piovella F, Ockleford PA, Brandies DPM, van der Meer J, Gallus AS, Simmoneau G, Chesterman CH, Prins MH, Bossuyt PMMM, de Haes H, van den Belt AGM, Sagnard L, D'Azemar, Buller HR for the TASMAN study group. Treatment of venous
thrombosis with intravenous unfractionated heparin administered in the hospital as compared with sub-cutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
Hull RD, Raskob GE, Pinco GF, et al. A randomized double blind trial of low molecular weight heparin in
the initial treatment of proximal vein thrombosis [abstractl. Thromb Haemost 1991;65:872.
Kay R, Sing Wong K, Yu YL, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
FRISC study group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S. Ludwig K on behalf of the FRIC Investigators. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks
in the management of unstable coronary artery disease. Fragmin in unstable coronary heart disease study (FRIC). Circulation 1997;96:61-8.
Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
Faxon D, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis Cera Trial. Circulation 1994;90:908-14.
Cairns JA, Gill J, Morton B, Roberrs R, Gent M, Hirsh, Holder D, Finnie K, Marquis JE Naqvi S, Cohen E and the EMPAR collaborators. Fish oils and low molecular weight heparin for the reduction of restenosis following percutaneous transluminal coronary angioplasty (PTCA).
The EMPAR Study. Circulation 1996;94:1553-60.
Verstraete M. Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorhagic balance. Thromb Haemost 1997;78:357-63.
Becker RD, Cannon CP. Hirudin. Its biology and clinical use. J Thromb Thrombol Ther 1994;1:7-16.
Weitz JI, Califf RM, Ginsberg JS, et al. New antithrombotics. Chest 1995;108:471S-85S.
Eriksson BI, Jorgensen PW, Kilebo P, et al. A comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35.
Eriksson BI, Ekman S, Kuebo P, et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393 Lancet 1996;347:635-9.
Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombininant hirudin: results of a double-blind, multi-center trial comparing the efficacy of desirudin (Revase) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-33.
Topol EJ for the GUSTO IIb Investigators. Results of the Gusto IIb trial. 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 24-27, 1996.
The TIMI Investigators. TIMI 9B, American Heart Association 68th Annual Scientific Sessions, Anaheim, CA, November 13-16, 1995.
Esmon CT.' The regulation of natural anticoagulant
pathways. Science 1987;235:1348-52.
Hanson SR, Griffin JH, Harker LA, et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993,92:2003-12.
Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-46.
Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993;70:212-6.
Tuszyuski G, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. J Biol Chem 1987;262:9718-23.
Sitko GR, Ramjit DR, Inez I, et al. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992;85:805-15.
Marder VJ, Hirsh J, Bell WR. Rationale and practical basis of thrombolytic therapy. In: Colman RW, Hirsh J,
Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott 1994;1514-41.
Marder VJ. Thrombolytic therapy: Overview of results in major vascular occlusion. Thromb Haemost 1995;74:101-5.
Collen D. Thrombolytic therapy. Thromb Haemost 1997;78:742-6.
Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-24.
Collen D, Lijnen HR. Staphylokinase, a fibrin specific plasmiogcn activator with therapeutic potential? Blood 1994;84:680-6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
